Publications by Dr Jill Hunter - ePrints

Browsing publications by Dr Jill Hunter.

Newcastle Authors	Title	Year
Dr Jill Hunter Dr Elaine Willmore Professor Julie Irving Dr Stephany Veuger	Correction to: NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699 (Oncogene, (2012), 31, 2, (251-264), 10.1038/onc.2011.229)	2023
Dr Jack Leslie Dr Jill Hunter Amy Collins Amelia Rushton Lauren Russell et al.	c-Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis	2023
Dr Evan Mulligan Dr Susan Tudhope Dr Jill Hunter Sarah Elliott Dr Jonathan Wallis et al.	Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling	2023
Dr Suzanne Madgwick Dr Saimir Luli Helene Sellier Dr Jacqueline Butterworth Dr Jack Leslie et al.	Claspin haploinsufficiency leads to defects in fertility, hyperplasia and an increased oncogenic potential	2022
Dr Jill Hunter Dr Jacqueline Butterworth Helene Sellier Dr Nicola Hannaway Dr Saimir Luli et al.	Mutation of the RelA(p65) Thr505 phosphosite disrupts the DNA replication stress response leading to CHK1 inhibitor resistance	2022
Dr Jill Hunter Dr Nicola Hannaway Scott Kerridge Dr Saimir Luli Dr Jacqueline Butterworth et al.	Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway	2022
Dr Jill Hunter Scott Kerridge Dr Nicola Hannaway Dr Saimir Luli Dr Iglika Ivanova et al.	Up-regulation of the PI3K/AKT and RHO/RAC/PAK signalling pathways in CHK1 inhibitor resistant Eµ-Myc lymphoma cells	2022
Dr Jill Hunter Lucy Salmon Dr Caroline Wilson Professor Neil Perkins Dr Owen Davies et al.	Centrosome dysfunction associated with somatic expression of the synaptonemal complex protein TEX12	2021
Dr Anna Moles Fernandez Dr Jacqueline Butterworth Dr Jill Hunter Dr Jack Leslie Helene Sellier et al.	A RelA(p65) Thr505 phospho-site mutation reveals an important mechanism regulating NF-kB dependent liver regeneration and cancer	2016
Dr Jill Hunter Jack Leslie Professor Neil Perkins	c-Rel and its many roles in cancer: an old story with new twists	2016
Dr Jill Hunter Professor Neil Perkins	The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma	2016
Dr Jill Hunter Dr Jacqueline Butterworth Helene Sellier Huw Thomas Dr Christopher Bacon et al.	The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma	2016
Dr Anna Moles Fernandez Dr Jacqueline Butterworth Dr Jill Hunter Professor Derek Mann Professor Fiona Oakley et al.	Mutation of Rela THR505 Enhances Liver Regeneration Following Partial Hepatectomy	2015
Dr Elaine Willmore Dr Aaron Ions Gardner Dr Susan Tudhope Belinda Murtani Jessica Caffry et al.	Novel small molecule IKK alpha inhibitors inhibit non- canonical NF-kappa B signaling and survival of primary CLL cells	2015
Dr Ashleigh Herriott Dr Susan Tudhope Gesa Junge Natalie Rodrigues Dr Miranda Patterson et al.	PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia	2015
Dr Anna Moles Fernandez Dr Jacqueline Butterworth Dr Jill Hunter Dr Dina Tiniakos Professor Derek Mann et al.	Thr505 RelA phosphorylation controls liver proliferative response and supresses NF-kappa B tumor-promoting activities	2015
Dr Adeline Ledoux Dr Jill Hunter Professor Neil Perkins	Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy	2014
Dr Jill Hunter Dr Jacqueline Butterworth Professor Neil Perkins Professor Melissa Bateson Dr Claire Richardson et al.	Using body temperature, food and water consumption as biomarkers of disease progression in mice with Eμ-myc lymphoma	2014
Dr Jill Hunter Dr Elaine Willmore Professor Julie Irving Dr Stephany Veuger Professor barbara Durkacz et al.	NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699	2012
Dr Susan Tudhope Dr Evan Mulligan Dr Jill Hunter Dr Helen Marr Professor barbara Durkacz et al.	P B S-1086, a "Pan-Rel" Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells	2012